Incannex Healthcare shares rise 2.88% premarket after positive Phase 2 study results for IHL-42X asset.

Incannex Healthcare Inc. rose 2.88% in premarket trading, with Stonegate Capital Partners updating their coverage on the company. The update highlighted significant progress on the IHL-42X asset, following very positive topline results from the Phase 2 study. Both the low and high dose groups achieved a statistically significant reduction in the Apnoea-Hypopnoea Index (AHI) from baseline compared to placebo, indicating a successful outcome.